What are the latest advances in Hemicrania Continua?

Hemicrania Continua is a rare, strictly unilateral headache disorder characterized by a continuous, fluctuating pain that is uniquely responsive to indomethacin. Recent research is shifting from traditional pharmacological management toward investigating the role of calcitonin gene-related peptide (CGRP) monoclonal antibodies and neurostimulation techniques for patients who cannot tolerate or do not respond to indomethacin.

What are the current research directions for Hemicrania Continua?

While indomethacin remains the gold standard diagnostic and therapeutic tool for Hemicrania Continua, researchers are increasingly focused on identifying non-steroidal alternatives. The most promising research involves the use of CGRP-targeting therapies, which have revolutionized migraine treatment and are now being studied for their efficacy in managing Hemicrania Continua refractory to standard care. Additionally, clinical interest is growing in neuromodulation, specifically non-invasive vagus nerve stimulation, as a potential adjunctive therapy for those living with Hemicrania Continua.

Are there new treatments or clinical trials for Hemicrania Continua?

Current clinical research is limited by the rarity of the condition, yet several observational studies and case series are actively exploring personalized treatment protocols. Patients interested in participating in research or finding ongoing trials should monitor the following resources:

• ClinicalTrials.gov: Search specifically for "Hemicrania Continua" to view active, recruiting, or completed interventional studies.


• CGRP Monoclonal Antibodies: Studies are evaluating if drugs like galcanezumab or erenumab can reduce the frequency and intensity of pain in Hemicrania Continua patients.


• Real-world evidence: Platforms like DiseaseMaps.org, where 86 members have shared their experiences, are becoming vital for researchers to understand the long-term progression of Hemicrania Continua.

How can patients contribute to Hemicrania Continua research?

Because Hemicrania Continua is rare, patient-reported data is essential to clinical progress. By documenting symptoms and treatment outcomes within large registries, patients help refine the diagnostic criteria and identify potential biomarkers. Participating in institutional studies or joining patient-led research initiatives provides researchers with the necessary data to secure funding for larger, randomized controlled trials.

Next steps

• Consult a headache specialist or neurologist to discuss if you meet the specific diagnostic criteria for Hemicrania Continua.


• Visit ClinicalTrials.gov regularly to check for new, registered trials.


• Connect with the 86 members of our DiseaseMaps community to share insights and stay informed about emerging patient-led research efforts.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician regarding a medical condition.

References

• NIH Genetic and Rare Diseases (GARD) Information Center - Hemicrania Continua profile.


• Orphanet - Rare disease database entry for Hemicrania Continua (ORPHA:3976).


• The American Headache Society (AHS) clinical practice guidelines for primary headache disorders.


• PubMed/MEDLINE - Current literature reviews on indomethacin-responsive headaches.